Skip to main content
H.R. 2408 118th Congress House

Access to Innovative Treatments Act of 2023

Official title: To amend title XVIII of the Social Security Act to provide a review process for adverse national coverage determinations with respect to drug coverage under the Medicare program.

Introduced: March 30, 2023 Introduced by: Nanette Diaz Barragán Democratic · California See on congress.gov
Health
Sign in to write a letter Sign in to watch
This bill died when the 118th Congress ended
It never became law before the 118th Congress (2023–2024) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Dec 17, 2024
Referred to the Subcommittee on Health.
Apr 7, 2023
Referred to the Subcommittee on Health.
Mar 30, 2023
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Mar 30, 2023
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action December 17, 2024

Referred to the Subcommittee on Health.

 Plain-English summary Congressional Research Service

Access to Innovative Treatments Act of 2023

This bill requires the Centers for Medicare & Medicaid Services (CMS) to review adverse national coverage determinations of drugs under Medicare within 30 days of receiving a request to do so. (Under the bill, adverse national coverage determinations are denials or limitations of coverage that are inconsistent with the drug's approval by the Food and Drug Administration.) The bill's requirements do not apply if the CMS already conducted such a review within a two-year period.

The bill also prohibits the CMS from applying prior coverage determinations that were made for drugs before they were approved by the FDA if such determinations are inconsistent with the drug's approval.

 Related & companion bills 1
  • HR 9358 Reintroduction of Access to Innovative Treatments Act of 2022
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 4
 Lobbying activity 9

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

Bodies those filers lobbied

A filing lists the bills it worked on and the parts of government it contacted in separate sections, so these are the bodies those filers named anywhere in the filing, not a per-bill breakdown.

See all 9 filings →
 Cosponsors 1
All 1 Republican 1
R
Joyce, John
Pennsylvania · Mar 30, 2023
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 2408: Access to Innovative Treatments Act of 2023. 118th Congress. Open America. https://openamerica.io/bill/118-HR-2408/
MLA
"H.R. 2408: Access to Innovative Treatments Act of 2023." 118th Congress, 2026, Open America, https://openamerica.io/bill/118-HR-2408/.
Bluebook (legal)
H.R. 2408, 118th Cong. (2026), https://openamerica.io/bill/118-HR-2408/.
Markdown link
[H.R. 2408: Access to Innovative Treatments Act of 2023](https://openamerica.io/bill/118-HR-2408/)
Report a problem